NCT02230553View on ClinicalTrials.gov

Lapatinib Plus Trametinib in KRAS Mutant NSCLC

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

October 7, 2014

Primary Completion Date

July 29, 2019

Study Completion Date

August 6, 2019

Conditions

Colorectal Cancer

Interventions

DRUG

Lapatinib

DRUG

trametinib

Trial Locations (1)

1066CX

The Netherlands Cancer Institute, Amsterdam

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT02230553 - Lapatinib Plus Trametinib in KRAS Mutant NSCLC | Biotech Hunter | Biotech Hunter